function MajorInitiatives(){

    var s=new Array()

    s[0]='<p><a href="/MajorInitiatives/Steering_Committees.htm" class="red">Restructuring NCI Clinical Trials  Prioritization Process &ndash; Steering Committees</a><br />The Disease-Specific  Scientific Steering Committees will leverage existing Intergroup, Cooperative  Group, SPORE, and Cancer   Center structures for  each major disease area as well as for pediatric oncology and symptom  management/supportive care to address, design and prioritize phase 3  trials. <a href="/MajorInitiatives/Steering_Committees.htm" class="red">More&#8230;</a></p>';
    s[1]='<p><a href="/MajorInitiatives/Collaboration_with_NHLBI.htm" class="red">Collaboration with NHLBI on the BMT-CTN</a><br />The Blood  and Marrow Clinical Trials Network (BMT CTN) is supported by a U01 grant to the  NHLBI and NCI, with the NHLBI as the lead institute. NIAID also supports one of the trials. This network is managed jointly among NHLBI  and NCI/CTEP program officers. The BMT  CTN was established in October of 2001 to conduct large, multi-institutional  clinical trials addressing important issues in hematopoietic stem cell transplantation (HCT). <a href="/MajorInitiatives/Collaboration_with_NHLBI.htm" class="red">More&#8230;</a></p>';
    s[2]='<p><a href="/MajorInitiatives/Cancer_Trials_Support_Unit.htm" class="red">Cancer Trials Support Unit (CTSU)</a><br />The Cancer Trials  Support Unit (CTSU) is a service of the National Cancer Institute&rsquo;s (NCI)  Cancer Therapy Evaluation Program (CTEP). The goals of the CTSU are to provide a wide choice of NCI-sponsored clinical trials to patients, investigators and  sites&#59; increase the speed of completion of critical cancer trials, resulting in the identification of novel treatments for cancer patients, <a href="/MajorInitiatives/Cancer_Trials_Support_Unit.htm" class="red">More&#8230;</a></p>';
    s[3]='<p><a href="/MajorInitiatives/Central_Institutional_Review_Board_Initiative.htm" class="red">Central Institutional Review Board Initiative (CIRB)</a><br />The Central  Institutional Review Board Initiative (CIRB) provides an innovative approach to  human subject protection through a &ldquo;facilitated review&rdquo; process that  streamlines local IRB review of adult and pediatric national multi-center  cancer treatment trials. The Initiative consists of two central IRBs, one for  adult trials and one for pediatric trials. The adult CIRB reviews all phase 3 <a href="/MajorInitiatives/Central_Institutional_Review_Board_Initiative.htm" class="red">More&#8230;</a></p>';
    s[4]='<p><a href="/MajorInitiatives/Phase_1-2_Early_Drug_Development.htm" class="red">Phase 1-2 Early Drug Development</a><br />The CTEP  Early Drug Development Program (EDDP), under the direction of the  Investigational Drug Branch, carries out drug development plans for  investigational agents held under CTEP   IND, in collaboration with  industry, academia, and the NCI intramural program. CTEP currently holds  approximately 80 active INDs, with more than 500 phase 1-2 clinical trials. The primary funded components of the CTEP EDDP include the Phase 1 U01 grantees and <a href="/MajorInitiatives/Phase_1-2_Early_Drug_Development.htm" class="red">More&#8230;</a></p>';
    s[5]='<p><a href="/MajorInitiatives/Early_Drug_Development_Meeting.htm" class="red">CTEP Early Drug Development (EDD) Meeting</a><br />CTEP sponsors two semi-annual investigator meetings, in the spring and fall of each year.  These meetings generally last one and a half days and are held either on the NIH Clinical Center campus (e.g. Natcher auditorium) or in a nearby hotel. The meeting is intended as an educational event and is focused on enhancing communications between the NCI and the network of CTEP-supported UO1 and NO1-funded early clinical trial investigators. <a href="/MajorInitiatives/Early_Drug_Development_Meeting.htm" class="red">More&#8230;</a></p>';
    s[6]='<p><a href="/MajorInitiatives/Michaele_C_Christian.htm" class="red">Michaele C. Christian  Oncology Development Lectureship and Award</a><br />This award  was established by the Cancer Therapy Evaluation Program in 2007 to honor the  twenty year NCI career of Michaele C. Christian.  Dr. Christian was  appointed Associate Director of the Cancer Therapy Evaluation Program of DCTD  in 1997 after serving as head of the Investigational Drug Branch overseeing the  clinical development of novel anticancer agents. <a href="/MajorInitiatives/Michaele_C_Christian.htm" class="red">More&#8230;</a></p>';
    s[7]='<p><a href="/MajorInitiatives/Organ_Dysfunction_Studies.htm" class="red">Organ Dysfunction Studies</a><br />The Cancer  Stem Cell (CSC) Therapeutics Initiative will evaluate agents (GSIs, kinase  inhibitors, DLL ligand inhibitors, antibodies, disruption of protein  interactions) that target the cancer stem cells/progenitor cells and their  altered embryonic signaling pathways, with a particular emphasis on Hedgehog  (SHh), notch and <em>wnt</em> signaling. The goals and objectives of this initiative include <a href="/MajorInitiatives/Organ_Dysfunction_Studies.htm" class="red">More&#8230;</a></p>';
    s[8]='<p><a href="/MajorInitiatives/Pharmaceutical_Collaborations.htm" class="red">Pharmaceutical Collaborations</a><br />The goal of the Cancer  Therapy Evaluation Program (CTEP) is to facilitate the process of bringing  promising, novel, investigational anticancer agents to the public as quickly  and as safely as possible. As part of meeting that goal, CTEP actively seeks  collaborations with pharmaceutical and biotechnology companies, specifically to  complement or enhance their clinical development plans, thereby expediting the  development of promising agents. <a href="/MajorInitiatives/Pharmaceutical_Collaborations.htm" class="red">More&#8230;</a></p>';
    s[9]='<p><a href="/MajorInitiatives/International_Trials.htm" class="red">International Trials &ndash; NCIC, EORTC, IBCSG and others</a><br />As improvements  in cancer treatment have led to increased survival, the need for expanded  collaboration on treatment trials has correspondingly increased. First, new  active treatments which prolong survival in turn often require larger sample  sizes to detect potential benefit from experimental regimens or to determine  the similar efficacy of a less toxic regimen. <a href="/MajorInitiatives/International_Trials.htm" class="red">More&#8230;</a></p>';
    s[10]='<p><a href="/MajorInitiatives/Pediatric_Preclinical_Testing_Program.htm" class="red">Pediatric  Preclinical Testing Program (PPTP)</a><br />The  NCI-supported Pediatric Preclinical Testing Program (PPTP) is a comprehensive  program to systematically evaluate new agents against childhood solid tumor and  leukemia models. The PPTP is supported through an NCI research contract to St.  Jude Children&#8217;s Research Hospital (SJCRH) with Dr. Peter Houghton as the  Principal Investigator. Testing occurs both at SJCRH and also <a href="/MajorInitiatives/Pediatric_Preclinical_Testing_Program.htm" class="red">More&#8230;</a></p>';
    s[11]='<p><a href="/MajorInitiatives/Adult_Brain_Tumor_Consortium.htm" class="red">Adult Brain Tumor Consortium</a><br />The Adult Brain Tumor Consortium (ABTC) is a new multi-institutional consortium created from the consolidation of two previous, separate NCI-funded consortia: the New Approaches to Brain Tumor Therapy (NABTT) and the North American Brain Tumor Consortium (NABTC). The newly formed ABTC permits NABTT and NABTC investigators to continue their research, but focuses management of their clinical program into a single entity. <a href="/MajorInitiatives/Adult_Brain_Tumor_Consortium.htm" class="red">More&#8230;</a></p>';
    s[12]='<p><a href="/MajorInitiatives/Childhood_Cancer_Survivor_Study.htm" class="red">The Childhood Cancer Survivor Study</a><br />The Childhood Cancer Survivor  Study (CCSS) is a collaborative, multi-institutional study funded by the  National Cancer Institute since 1993.  The goal of CCSS is to investigate the long-term morbidity and mortality  associated with the treatment regimens for children and adolescents treated for  cancer during the past 30 years. It was created to gain new knowledge about the long-term effects of cancer and therapy <a href="/MajorInitiatives/Childhood_Cancer_Survivor_Study.htm" class="red">More&#8230;</a></p>';
    s[13]='<p><a href="/MajorInitiatives/Childrens_Oncology_Group.htm" class="red">The Children&rsquo;s  Oncology Group (COG) Phase I/Pilot Consortium</a><br />The  consortium&rsquo;s primary objective is to expeditiously develop and implement pediatric  phase I and pilot studies, thus facilitating the integration of advances in  cancer biology and therapy into the treatment of childhood cancer. The  consortium includes approximately 20 pediatric COG institutions with expertise  and experience in developmental therapeutics. <a href="/MajorInitiatives/Childrens_Oncology_Group.htm" class="red">More&#8230;</a></p>';
    s[14]='<p><a href="/MajorInitiatives/Common_Terminology_Criteria.htm" class="red">Common Terminology Criteria for Adverse Events</a><br />Cancer  Therapy Evaluation Program (CTEP) developed the original Common Toxicity  Criteria (CTC) in 1983 to aid in standardizing the description of adverse  events (AEs) and grading the severity of those events for oncology clinical  trials with therapeutic interventions. The CTC was revised twice. The  Common Terminology Criteria for Adverse Events version 3 (CTCAEv3) was  implemented in 2003, <a href="/MajorInitiatives/Common_Terminology_Criteria.htm" class="red">More&#8230;</a></p>';
    s[15]='<p><a href="/MajorInitiatives/Pediatric_Brain_Tumor_Consortium.htm" class="red">Pediatric Brain Tumor Consortium</a><br />The Pediatric Brain Tumor  Consortium (PBTC) was formed by the National Cancer Institute (NCI) in 1999 as  a clinical trials organization dedicated to translating innovative therapies  from the laboratory to early phase clinical testing so that treatment for  primary brain tumors in children can be improved. The importance of the PBTC is highlighted by  the continuing high mortality rate, <a href="/MajorInitiatives/Pediatric_Brain_Tumor_Consortium.htm" class="red">More&#8230;</a></p>';


    var n=Math.floor(Math.random()*(s.length))
    document.write(s[n])

    }